Pancragen 20mg

Pancragen is a tetrapeptide (Lys-Glu-Asp-Pro) from the Khavinson series targeting pancreatic tissue — specifically islet cell biology and exocrine pancreas function. It shares its sequence with Livagen (Lys-Glu-Asp-Pro), which targets the liver. That shared sequence with different tissue targets is one of the more interesting aspects of the Khavinson framework: the hypothesis is that tissue specificity emerges from distribution following administration, not from the peptide sequence alone. The same sequence reaching pancreatic cells is proposed to interact with different available promoter sites than the same sequence reaching hepatocytes.

The pancreas is an interesting bioregulation research context for researchers in the metabolic space. Beta cell function and islet biology are central to diabetes and glucose homeostasis, and the transcriptional programs governing insulin secretion capacity change significantly with aging and metabolic stress. The Khavinson group has published on pancreatic bioregulators examining gene expression in pancreatic acinar cells and islets, with attention to age-related changes in insulin secretion capacity and exocrine function.

Research Context

For researchers working in the GLP-1 and incretin space: Pancragen represents a mechanistically different approach to pancreatic biology — tissue-level gene expression modulation rather than receptor agonism. Whether the two approaches produce complementary or independent effects in the same model is an open research question.

Specifications

Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.

Quality: HPLC purity analysis, mass spec identity confirmation, endotoxin testing on every batch. COA ships with every order. EU-based QC under CERTALAB S.R.L.

For research purposes only. Not for human consumption.